Arteriovenous fistula (AV) - Pipeline Insight, 2025

DelveInsight’s, “Arteriovenous fistula – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Arteriovenous fistula pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Arteriovenous fistula Understanding

Arteriovenous fistula: Overview

Arteriovenous fistula (AV) is an abnormal connection between an artery and a vein, in which blood flows directly from an artery into a vein, bypassing some capillaries. Small arteriovenous fistulas in your legs, arms, lungs, kidneys or brain are not much complicated while a large untreated arteriovenous fistula can lead to serious complications. An AV can develop anywhere in the body, though typically occur in the head, neck, spine, and liver. They can be caused from congenital defects or acquired as a results of cardiac catheterization complication, injuries that pierce the skin, and genetic conditions. Arteriovenous fistulas are often surgically created by vascular surgeon for use in dialysis in people with severe kidney disease. A diagnosis of Arteriovenous fistula (AV) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Tests to diagnose an Arteriovenous fistula can include: Duplex ultrasound, Computerized tomography (CT) angiogram, and Magnetic resonance angiography (MRA). For small arteriovenous fistula a close monitoring by a doctor is sufficient, these fistula may close by themselves without treatment. Treatment options for large fistula includes endovascular embolization, ultrasound-guided compression, microsurgery, or stereotactic radiosurgery.

""Arteriovenous fistula - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Arteriovenous fistula pipeline landscape is provided which includes the disease overview and Arteriovenous fistula treatment guidelines. The assessment part of the report embraces, in depth Arteriovenous fistula commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Arteriovenous fistula collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Arteriovenous fistula R&D. The therapies under development are focused on novel approaches to treat/improve Arteriovenous fistula.

Arteriovenous fistula Emerging Drugs Chapters

This segment of the Arteriovenous fistula report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Arteriovenous fistula Emerging Drugs

• Liposome encapsulated prednisolone: Enceladus Pharmaceuticals

Liposome encapsulated prednisolone is an arachidonic acid inhibitors being developed and investigated in Phase II clinical trial to treat Arteriovenous fistula. In preclinical studies Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model.

Further product details are provided in the report……..

Arteriovenous fistula: Therapeutic Assessment

This segment of the report provides insights about the different Arteriovenous fistula drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Arteriovenous fistula

There are approx. 3+ key companies which are developing the therapies for Arteriovenous fistula. The companies which have their Arteriovenous fistula drug candidates in the most advanced stage, i.e. Phase II include, Enceladus Pharmaceuticals.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Arteriovenous fistula pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Arteriovenous fistula: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Arteriovenous fistula therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Arteriovenous fistula drugs.

Arteriovenous fistula Report Insights

• Arteriovenous fistula Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Arteriovenous fistula Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Arteriovenous fistula drugs?
• How many Arteriovenous fistula drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Arteriovenous fistula?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Arteriovenous fistula therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Arteriovenous fistula and their status?
• What are the key designations that have been granted to the emerging drugs?